SOURCE: Edwards Lifesciences

Edwards Lifesciences

February 05, 2014 09:15 ET

Edwards' SAPIEN XT Valve Approved in Europe for Transcatheter Mitral and Aortic Valve-in-Valve Procedures

IRVINE, CA--(Marketwired - Feb 5, 2014) - Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced it has received CE Mark in Europe for valve-in-valve procedures using the SAPIEN XT transcatheter heart valve, providing a minimally invasive treatment option for patients whose surgical mitral or aortic valves require replacement, and who are at extreme risk for surgery. Edwards is the only company to receive a valve-in-valve indication for the mitral position, which addresses an unmet need within the clinical community to provide an alternative to a high-risk surgery.

"The European approval of the SAPIEN XT system for valve-in-valve procedures is a milestone achievement. While this is not a large financial opportunity, it represents an important benefit for patients unable to go through a second open-heart surgery to replace their failing bioprosthetic valves," said Larry L. Wood, Edwards' corporate vice president, transcatheter heart valves.

More than 300,000 valve replacements are performed worldwide each year through open-heart surgery, utilizing either bioprosthetic tissue valves or mechanical valves. Edwards' proven family of PERIMOUNT bovine pericardial tissue valves have been the world's most frequently implanted valves for more than 30 years, which surgeons have increasingly chosen over mechanical valves, even in younger patients. Patients who receive Edwards' bovine pericardial valves are generally not required to be on lifelong anticoagulation therapy (blood thinners), as they would if they had received a mechanical valve. Decades of clinical experience and peer-reviewed data on Edwards' valves provide robust evidence of long-term performance and optimal hemodynamics of the PERIMOUNT valve platform.

"Just as native heart valves experience wear over time, bioprosthetic valves eventually degenerate, too, creating a need for a replacement valve," said Olaf Wendler, M.D., Ph.D., professor of cardiac surgery, King's College Hospital in London, and one of the principal investigators of the SOURCE XT Registry. "The European adoption of valve-in-valve procedures using SAPIEN XT is an important development for treating patients who may otherwise go untreated. In particular, patients needing a re-operation to address a failing mitral valve face a very challenging surgery, and the ability to offer a transcatheter replacement is extremely important for this patient group." Dr. Wendler provides paid consulting services to Edwards for education, and research and development of transcatheter valve technologies.

In the United States, the SAPIEN XT valve is not commercially available; it is an investigational device being studied as part of the randomized, pivotal PARTNER II Trial.

About Edwards Lifesciences
Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, statements of Mr. Wood and Dr. Wendler and statements about treatment trends and potential patient benefits. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement.

Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors, including but not limited to, unexpected outcomes after more extended clinical experience, unanticipated regulatory or quality issues, and changes in patient and market dynamics. These factors are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2012.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, SAPIEN, SAPIEN XT, PARTNER and PARTNER II are trademarks of Edwards Lifesciences Corporation.

Contact Information

  • Media Contact:
    Sarah Huoh

    Investor Contact:
    David K. Erickson